Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entera Bio (ENTX) Change in Working Capital (2019 - 2021)

Entera Bio has reported Change in Working Capital over the past 3 years, most recently at -$345000.0 for Q2 2021.

  • For the quarter ending Q2 2021, Change in Working Capital rose 46.01% year-over-year to -$345000.0, compared with a TTM value of -$345000.0 through Jun 2021, up 46.01%, and an annual FY2020 reading of -$351000.0, down 150.8% over the prior year.
  • Change in Working Capital came in at -$345000.0 for Q2 2021, up from -$639000.0 in the prior quarter.
  • In the past five years, Change in Working Capital ranged from a high of $255000.0 in Q2 2019 to a low of -$639000.0 in Q2 2020.
  • Median Change in Working Capital over the past 3 years was -$345000.0 (2021), compared with a mean of -$243000.0.
  • The sharpest move saw Change in Working Capital crashed 350.59% in 2020, then soared 46.01% in 2021.
  • Over 3 years, Change in Working Capital stood at $255000.0 in 2019, then crashed by 350.59% to -$639000.0 in 2020, then soared by 46.01% to -$345000.0 in 2021.
  • Per Business Quant, the three most recent readings for ENTX's Change in Working Capital are -$345000.0 (Q2 2021), -$639000.0 (Q2 2020), and $255000.0 (Q2 2019).